Castle Biosciences Inc (CSTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has a cash flow conversion efficiency ratio of -0.048x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.13 Million) by net assets ($461.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Castle Biosciences Inc to measure how many days the company can operate on defensive assets alone.
Castle Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Castle Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Castle Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dap Gayrimenkul Gelistirme AS
IS:DAPGM
|
0.016x |
|
Ridgepost Capital, Inc
NYSE:RPC
|
0.042x |
|
Huasu Holdings Co Ltd
SHE:000509
|
-0.215x |
|
Yesway, Inc. Class A Common Stock
NASDAQ:YSWY
|
-47546.000x |
|
Sinoma Energy Conservation Ltd
SHG:603126
|
-0.039x |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
|
0.011x |
|
Solid Power Inc
NASDAQ:SLDP
|
-0.036x |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
0.077x |
Annual Cash Flow Conversion Efficiency for Castle Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Castle Biosciences Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Castle Biosciences Inc (CSTL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $470.87 Million | $64.35 Million | 0.137x | -3.97% |
| 2024-12-31 | $455.83 Million | $64.87 Million | 0.142x | +1089.66% |
| 2023-12-31 | $391.27 Million | $-5.63 Million | -0.014x | +86.22% |
| 2022-12-31 | $399.15 Million | $-41.66 Million | -0.104x | -126.35% |
| 2021-12-31 | $411.74 Million | $-18.98 Million | -0.046x | -294.27% |
| 2020-12-31 | $415.69 Million | $9.87 Million | 0.024x | -71.21% |
| 2019-12-31 | $85.11 Million | $7.01 Million | 0.082x | -93.25% |
| 2018-12-31 | $-10.07 Million | $-12.29 Million | 1.221x | +42.44% |
| 2017-12-31 | $-14.27 Million | $-12.23 Million | 0.857x | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more